

CrossMark
click for updatesCite this: *RSC Adv.*, 2015, 5, 96809

Benzofuran: an emerging scaffold for antimicrobial agents

Asha Hiremathad,^{†ab} Mahadeo R. Patil,^{†a} Chethana K. R.,^a Karam Chand,^b M. Amelia Santos^b and Rangappa S. Keri^{*a}

Resistance to antibiotics is a major global problem and there is an urgent need to develop new therapeutic agents. Although many classes of active compounds have been established as efficient derivatives in diverse fields of antimicrobial therapy, they have not yet found wide application against a few deadly microbes. In recent years, compounds have been developed that have solved some of the problems posed; for example improved bioavailability is one of the targets achieved with most of the more recent compounds, allowing for once-daily dosing. Benzofuran and its derivatives are found to be suitable structures, existing widely in natural products and unnatural compounds with a wide range of biological and pharmacological applications; thus, considerable attention has been focused on the discovery of new drugs in the fields of drug invention and development. Some benzofuran derivatives, such as psoralen, 8-methoxypsoralen and angelicin have been used in the treatment of skin diseases such as cancer or psoriasis. The unique structural features of benzofuran and its wide array of biological activities make it a privileged structure in the field of drug discovery, especially in the search for efficient antimicrobial candidates. Recently, this scaffold has emerged as a pharmacophore of choice for designing antimicrobial agents that are active toward different clinically approved targets. To pave the way for future research, there is a need to collect the latest information in this promising area. In the present review, we collated the published reports on this versatile core to provide a deeper insight, so that its full therapeutic potential can be utilized for the treatment of microbial diseases. This study systematically provides a comprehensive report on current developments in benzofuran-based compounds as antimicrobial agents and is also helpful for the researchers working on a substitution

Received 6th October 2015
Accepted 27th October 2015

DOI: 10.1039/c5ra20658h

www.rsc.org/advances

^aCentre for Nano and Material Sciences, Jain University, Jain Global Campus, Jakkasandra post, Kanakapura Road, Ramanagara District, Bangalore 562112, Karnataka, India. E-mail: keriphad@gmail.com; sk.rangappa@jainuniversity.ac.in; Fax: +91 9620667075; Tel: +91 8027577199

^bCentro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal

† Equal contribution from both the authors.



Asha Hiremathad graduated (B.Sc.) from Karnataka University in 2011 (India) and received a M.Sc. in Organic chemistry from NMKRV College for Women, affiliated to Bangalore University (India) in 2013. Presently she is working as a doctoral student in CNMS, Bangalore, India, under the guidance of Dr Rangappa Keri Ph.D. Her research interests include synthesis of multi-

targeting drug candidates against Alzheimer's disease and their mechanisms in organic chemistry and biology.



Mahadeo R. Patil received his M.Sc. degree in organic chemistry in 2007 from S.R.T.M. University, Nanded, Maharashtra, India. Then, he moved to NCL (CSIR lab), Pune, India, as a project assistant. Furthermore, he spent 4 years at IOCB, Prague, Czech Republic, to work on a research project as an assistant scientist. There his research work focused on the synthesis of isotopically labelled brassinos-

teroids and their application. Presently, he is working as a doctoral student in CNMS, Bangalore, India, under the guidance of Dr Rangappa Keri and his research is mainly focused on the synthesis and biological activity of novel heterocyclic compounds.

pattern around the nucleus, with an aim to help medicinal chemists to develop structure activity relationships (SAR) on these derivatives as antimicrobial drugs.

1. Introduction

Contagious microbial diseases are increasing with the course of time around the world due to the emergence of new multidrug-resistant bacteria, resulting from the development of mutagenicity.¹ They are a major cause of morbidity and mortality, especially in people who are immunosuppressed and patients who acquire them in hospitals.² The challenge that is more crucial than ever is the conscious usage of the currently marketed antibiotics and also development of novel efficient antibiotic agents.^{3,4} In view of this, it is imperative to discover new chemotherapeutic agents to prevent the emergence of resistance and ideally shorten the duration of therapy. From this perspective, one of the best ways to design new antimicrobial agents is to synthesize/generate bioactive heterocyclic moieties using a single molecular scaffold.



Chethana K. R. graduated from Mysore University in 2007 and received a master's degree in Biochemistry from Mangalore University in 2009. Currently, she is working as a doctoral student under the supervision of Dr Rangappa Keri Ph.D., in CNMS, Jain University, Bangalore, India. Her research interests include screening of natural herbs and drug candidatures for therapeutics of Alzheimer's disease.



Karam Chand obtained his Ph.D. in organic chemistry in 2013 from the University of Delhi, India, under the supervision of Prof. Sunil K. Sharma. He is currently an Erasmus Namaste postdoctoral fellow in the research group of Prof. M. Amélia Santos at Instituto Superior Tecnico, University of Lisboa, Portugal. He did his B.Sc. at Himachal Pradesh University, Shimla, India

(2004), and his Master's at Gurukula Kangri Vishwavidyalaya (Haridwar), Uttarakhand, India, in 2006. His research interests include: organic synthesis, biocatalysis, and chemistry of natural products for the development of bioactive compounds and their targeted delivery.

Heterocyclic ring systems are powerful backbones with many biological properties. Among the heterocyclic compounds, benzofuran derivatives are an important class of compounds, occupying a place in numerous bioactive natural products. Benzofuran was synthesized for the first time by Perkin in 1870.⁵ Subsequently, the research and development of benzofuran-based biologically active compounds has been a rapidly developing and increasingly active field due to their wide potential applications as medicinal drugs (pharmaceuticals), agrochemicals, molecular electronic and functional polymers, man-made materials, artificial acceptors, and supramolecular ligands.⁶ In particular, the application of benzofuran derivatives in medicinal chemistry has achieved great progress. Many benzofuran-anchored drugs play an important role in the treatment of various types of diseases and new benzofuran derivatives with medicinal value are being actively explored worldwide.⁷ The accepted name for ring system **1** (shown in Fig. 1) in chemical abstracts is benzo(*b*)furan. To shorten this, (*b*) is conveniently dropped and it is commonly known by the generic name benzofuran. The name, coumarone, used in earlier literature for this nucleus is now rejected. The positions of benzofuran ring are numbered starting from heteroatom, as shown in Fig. 1.

Benzofuran derivatives exhibit significant activity including antifungal,^{8,9} antiprotozoal,⁸ antitubercular,¹⁰ antiinflammatory,¹¹




Fig. 1 Structure/numbering system in benzofuran.



Dr Rangappa S. Keri is currently working as an Assistant professor at Jain University, Bangalore, India. Before joining Jain University, he did his post-doctoral work at Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal and Kyung Hee University, Seoul, South Korea. His research interest concern organic and medicinal chemistry; in particular, the development of new

drugs including acetyl acetylcholinesterase (AChE) inhibitors, anti-cancer, neuroprotective agents and anti-virals by organic synthesis. Moreover, he is involved in the development of organometal and metalloorgano-catalyzed enantioselective methods for the synthesis of heterocyclic scaffolds.

anticonvulsant,¹² anticancer,¹³ antiHIV,¹⁴ analgesic,¹⁵ antiparasitic,¹⁶ antihyperlipidemic,¹⁷ antioxidant,¹⁸ antidiabetic,¹⁹ antihypertensive,²⁰ antiplasmodial,²¹ anti-Alzheimer's,²² vasodilating and hypotensive,²³ and antiarrhythmic.²⁴ Moreover, some of the benzofuran derivatives have been demonstrated to be potent topoisomerase I inhibitors,²⁵ sigma receptors,²⁶ Pim-1 inhibitors,²⁷ farnesyl transferase inhibitors,²⁸ histamine H₃ receptors²⁹ and carbonic anhydrase inhibitors.³⁰ Moreover, this heterocyclic compound is found in various branches of chemical research, namely, in polymer^{31,32} and dye industries^{33,34} and in silver photography.^{35,36} Benzofuran derivatives are important heterocycles frequently found in both bioactive compounds and organic materials. A few benzofuran derivatives that are actively used in the pharmacological field are illustrated in Fig. 2. The members of the furocoumarin class of natural products including psoralen **2**, 8-methoxypsoralen **3** and angelicin **4** can cross-link with DNA upon light irradiation. As a result, they have been used for the treatment of skin diseases such as cancer or psoriasis.^{37–40} The natural product coumestrol **5** is found especially in soya beans and has estrogenic activity.⁴¹ Synthetic bioactive compounds containing benzofurans are also important, as exemplified by amiodarone **6**, which is an antiarrhythmic drug.^{42,43} Recently, benzofurans have also emerged as important structural elements for organic materials such as the organic transistor **7**.⁴⁴ (–)-1-(Benzofuran-2-yl)-2-propylaminopentane {(–)-BPAP} **8** is another benzofuran-based drug used as a catecholaminergic and serotonergic activity enhancer. This stimulates the impulse propagation mediated transmitter release of the neurotransmitters dopamine, norepinephrine and serotonin in the brain.⁴⁵ 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB) **9** and 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB) **10** are putative entactogen drugs of the phenethylamine and amphetamine classes.⁴⁶ 5-(2-Aminopropyl)benzofuran (5-APB) **11** and 6-(2-aminopropyl) benzofuran

(6-APB) **12** are triple monoamine reuptake inhibitors^{47,48} and 5-APB is also an agonist of the 5-HT_{2B} receptor.⁴⁸ This makes it likely that 5-APB would be cardiotoxic with long term use, as seen in other 5-HT_{2B} agonists such as fenfluramine and MDMA. 6-APB is an entactogenic compound of the phenethylamine and amphetamine classes.⁴⁹

Therefore, the vast range of biological effects associated with this scaffold has resulted in the benzofuran ring system being considered as a privileged structure. This has resulted in considerable effort being focused on benzofuran-based medicinal agents and the expanding research and developments have become rapidly developing and increasingly active domains of research and are extended to almost the whole range of medicinal field. To develop more effective and less toxic agents to treat infectious diseases is still a challenge for the pharmaceutical chemist. A large amount of effort has been invested in the past decade to develop benzofuran-based compounds as microbial agents that are active on different clinically approved therapeutic targets and show excellent therapeutic potency.

A spectrum of pharmacological activities exhibited by benzofuran and its derivatives has been reviewed by some researchers;⁵⁰ however, in this review, we focused on the applications of benzofuran scaffolds (as organic molecules, inorganic complexes and naturally occurring compounds) as antimicrobial agents in detail. By looking into the importance of this therapeutic area, we decided to collect literature on the antimicrobial potency of benzofurans, the indispensable anchor in medicinal chemistry. In this review, we have attempted to shed light and compile published reports on benzofuran derivatives along with some opinions on different approaches to help the medicinal chemists in designing future generation potent yet safer antimicrobial agents. The purpose




Fig. 2 Benzofuran core, a multifunctional nucleus.

of this review is to update the most recent reports on the development of microbial agents as potential drug candidates for the treatment of infectious diseases.

2. Chemistry of benzofuran

Benzofurans are a class of very important heterocyclic compounds existing widely in natural products and unnatural compounds with biological and pharmacological potentials. It is therefore not surprising that an enormous amount of research has been carried out to develop efficient synthetic methods for their assemblies. The most pertinent and often employed strategies involve the one-pot etherification and dehydrative cyclization of *o*-hydroxyacetophenones **13** under basic conditions.⁵¹ Other strategies include the dehydrative cyclization of *o*-hydroxybenzyl ketones **16** or *R*-(phenoxy)alkyl ketones **17** (Fig. 3)⁵² and the cyclization of aryl acetylenes using transition-metal catalysis.⁵³ Although numerous synthetic approaches have been developed to prepare this family of compounds during the past decades, general protocols for the synthesis of these compounds are still of high interest.⁵⁰

3. Structural requirements of benzofuran derivatives for antimicrobial activity

A close proximity exists between the chemistry of furan and benzofuran. The greater stability of benzofuran compared with furan is due to annelation of the benzene ring. Similar to furan, oxygen contributes 2π -electrons to form a 10π -electron system in the case of benzofuran. This compound belongs to a group that is commonly known as “electron rich” or “ π excessive” heteroaromatics. As anticipated of such compounds, the benzofuran ring is highly reactive towards electrophilic substitution; however, the overall reactivity of the furan ring in benzofuran is decreased by the annelated

benzene ring. Resonance considerations of such condensed systems indicate that electrophilic substitution should occur at C-3. This is true with the analogous heterocycle, indole and to some extent with thionaphthene. However, benzofuran undergoes electrophilic substitution almost exclusively at the C-2 position, in contrast to the general prediction. This unusual difference in orientation between benzofuran and thionaphthene is associated with the electronegativity of oxygen and sulphur. Because oxygen is more electronegative than sulphur, the unshared electrons around oxygen are held more tightly than those of sulphur. Thus, the strongly electronegative character of oxygen cuts down the extent to which an unshared pair interacts with the two double bonds to form the aromatic system. Therefore, benzofuran behaves to a considerable extent like an olefin. Due to this distortion of electrons, ionic structure **18** is of greater importance in benzofuran (Fig. 3) and consequently electrophilic substitution at the C-2 position is favored. However, in thionaphthene, the electronegativity of sulphur is secondary to the stabilizing influence of benzene resonance, and the ionic structure **20** with a negative charge at the C-2 position is of greater importance (Fig. 4).⁵⁴

From the collected literature, it is found that the benzofuran nucleus substituted at all positions with various substituents produces potent antimicrobial activity; however, the 1-position contains core oxygen and therefore it is unsubstituted. The 2-position of benzofuran may be unsubstituted, or isatin, pyrazoline, pyrazole, imidazole, oxadiazole with $-Cl$, $-OH$, hydrazides, 2-piperidine, 4-nitrophenyl hydrazones, acetyl group and 2,4-dichloro-isoxazole, 4-fluorophenyl-isoxazole substituents may enhance the antimicrobial activity. Similarly, good activity was observed when the 3-position was substituted with hydrazone, benzylidene, pyrazoline, acetyl group or methyl group. The 4-position of the benzofuran may be substituted or unsubstituted but good antimicrobial activity was exhibited when the substituent on the 4-position contained halogens or hydroxyl groups. The 5- or 6-position of the nucleus may be unsubstituted, and substituents with halogens, nitro and hydroxyl groups have also displayed potent antibacterial activity. To exhibit antibacterial activity, it is essential that benzofuran contains halogens, nitro and hydroxyl groups at positions 4, 5, and 6. Benzofuran with triazolo-thiadiazine containing phenyl, methylphenyl or bromophenyl at the 7-position displayed good antimicrobial activity (Fig. 5).




Fig. 3 General scheme for the synthesis of benzofuran derivatives.




Fig. 4 Orientation of benzofuran and thionaphthene.




Fig. 5 Benzofuran scaffold in antimicrobial agents.

4. Benzofuran derivatives as antimicrobial agents

Nowadays, a number of common and uncommon bacteria previously susceptible to common antimicrobials are reported to have developed resistance to diverse antibiotics. Initially, these bacteria caused significant nosocomial infections and were the cause of major morbidity and mortality in patients. More recently, they have spread to the community, causing severe illness in previously healthy and otherwise non-vulnerable patients.^{55–58} Owing to this increased microbial resistance, new classes of antimicrobial agents with other modes of action are needed to fight against the recent multidrug-resistant infections.

Mohamed *et al.* reported the synthesis of a series of benzofuran-based pyrazoline-thiazoles **21(a–d)** (Fig. 6) and fluorinated pyrazole-thiazole (**22–26**) derivatives and tested their potential antimicrobial activities against four Gram-positive bacteria (*Staphylococcus aureus* (*S. aureus* (SA)),

Bacillus subtilis (*B. subtilis* (BS)), *Bacillus megaterium* (*B. megaterium* (BM)), *Sarcina lutea*) and Gram-negative bacteria (*Klebsiella pneumoniae* (*K. pneumoniae* (KP)), *Pseudomonas aeruginosa* (*P. aeruginosa* (PA)), and *Escherichia coli* (*E. coli* (EC))). Among these compounds, **21c** displayed excellent antimicrobial activity and highest potency against all the tested organisms with respect to reference drugs (ciprofloxacin and ketoconazole). Compounds **21d** and **22b** inhibited the growth of *S. aureus* with inhibition zones (IZ) of 23 and 20 mm, respectively, while compound **22a** evidenced promising antifungal activity against *K. pneumoniae*, *P. aeruginosa*, and *E. coli* with an IZ of about 24 mm. Moreover, compound **21c** showed the highest activity against *S. aureus*, *S. cerevisiae*, and *C. albicans* with an IZ of about 23 mm. A SAR study revealed that the presence of a -chloro substituent on pyrazoline and pyrazole moieties (**21c** and **22a**) increases the antimicrobial activity (Fig. 6).⁵⁹

In the literature, we found that the antimicrobial activity of benzofuran derivatives appears to be more dependent on substitution at the heterocyclic furan ring than on substitution




Fig. 6 Structures of fluorinated 2-(3-(benzofuran-2-yl) pyrazol-1-yl) thiazoles.

at the aromatic moiety.⁶⁰ Telvekar and co-workers investigated a series of benzofuran-3-carbohydrazide derivatives and screened for their potential antifungal activity against *Candida albicans* (*C. albicans*). The combination of unsubstituted benzylidene and a chloro di-substituted benzofuran ring exhibited greater activity compared to the activity of other members. In the case of a benzofuran derivative substituted with two electron-withdrawing groups 27, the activity was increased around fourfold. The electron-withdrawing group on the benzofuran ring and the electron-donating group on the *para* position of the aromatic side chain showed good activity 28 (Fig. 7).⁶¹

Structural modification of clinically approved benzofuran-based antimicrobial drugs is an effective strategy to increase biological activity and broaden the active spectrum of current drugs. Therefore, there are some reports on amidrazone derivatives that were found to possess remarkable biological activities^{62,63} and additionally these compounds have been reported as precursors of some effective antifungal azoles.⁶⁴ Abdel-Aziz and co-workers presented the synthesis of benzofuran-amidrazones 29(a-e), 30a, b and 31(a-c) (Fig. 8) and screened their antifungal/antibacterial activities. These derivatives showed significant antifungal potency, which was more than their antibacterial potency. Compound 30b exhibited the highest potency against all the tested fungal organisms with respect to a reference drug, griseofulvin. *C. albicans* (MIC = 75 $\mu\text{g mL}^{-1}$) was the most sensitive fungus to griseofulvin (MIC = 75 $\mu\text{g mL}^{-1}$), followed by *Aspergillus fumigatus* (*A. fumigatus*), *Geotrichum candidum* (*G. candidum*) and *Syncephalastrum*

racemosum (*S. racemosum*). Moreover, the same compound exhibited activity (MIC = 75 $\mu\text{g mL}^{-1}$) against *S. aureus*, which is a little less than the standard drug amoxicillin (MIC = 50 $\mu\text{g mL}^{-1}$). A SAR study revealed that the piperidine moiety and 4-nitrophenylhydrazide functions are essential for potential antimicrobial activity. Piperidines, which are frequently found in the side chains of therapeutic agents, are not usually associated with pharmacophores; they simply serve as surrogates for open-chain tertiary amines (Fig. 8).⁶⁵

3-Methanone-6-substituted-benzofuran derivatives were synthesized by Liu and co-workers and evaluated for their *in vitro* antibacterial activities against *E. coli*, *S. aureus*, Methicillin-resistant *Staphylococcus aureus* (MRSA), *B. subtilis*, and *P. aeruginosa*. Some of the compounds 32(a-c) and 33 with MIC₈₀ = 0.78–12.5 $\mu\text{g mL}^{-1}$ displayed excellent antibacterial activities compared to the positive controls (cefotaxime and sodium penicillin). Compounds 34 and 35 displayed strain-specificity to *S. aureus* with MIC₈₀ = 3.12–12.5 $\mu\text{g mL}^{-1}$. SAR studies revealed that the hydroxyl group at the C-6 position of benzofuran is essential for antibacterial activity, and the functional groups at the C-3 position play an important role in the antibacterial selectivity of these compounds (Fig. 9).⁶⁶

Furthermore, a benzofuran skeleton bearing aryl substituents at the C-3 position through a methanone linker has also been investigated as an antibacterial agent. Compound 36a with a hydroxyl group at the C-4 position showed moderate antibacterial activity against *S. aureus* (MIC₈₀ = 0.39 mg mL⁻¹) and MRSA (MIC₈₀ = 0.78 mg mL⁻¹), compared to the positive control drugs. On the other hand, compounds with methylation of the hydroxyl group had reduced solubility and decreased antimicrobial abilities, and compounds with halogen substituents showed no antimicrobial activity, whereas compound 36b had favorable activity against *B. subtilis* (MIC₈₀ = 0.78 mg mL⁻¹).⁶⁷ Chandrashekar *et al.* demonstrated the synthesis and antimicrobial applications of 5-phenyl-1-benzofuran-2-yl derivatives and the biphenyl methanones 37 and 38(a-c). These derivatives exhibited antimicrobial activities with MIC values ranging between 0.001 and 0.5 $\mu\text{g mL}^{-1}$. The carbinols and tertiary alcohols corresponding to methanone exhibited no antimicrobial activity (Fig. 10).⁶⁸




Fig. 7 Structures of substituted benzofuran-3-carbohydrazide.




Fig. 8 Structures of benzofuran-arylamidrazone derivatives.




Fig. 9 Structures of 3-methanone-benzofuran derivatives.

Rao and co-workers reported a series of 2,4,6-trimethoxy benzofuran derivatives as antibacterial agents. The synthesized compound, benzofuran carbohydrazide, **39**, displayed excellent activities with IZs of 27 mm and 26 mm against *E. coli* and *S. aureus*, respectively, at 25 μg mL⁻¹, when compared with the standard drug norfloxacin (IZ = 25 mm) for the same strains. Moreover, benzofuran carboxylic acid, **40**, showed a remarkable activity against *P. aeruginosa* (IZ = 21 mm) and *S. pyogenes* (IZ = 23 mm), although a SAR study has not been reported for these compounds.⁶⁹ Soliman and co-workers described the synthesis of naturally occurring visnagin derivatives and tested for their antimicrobial activity against different bacterial and fungal strains. Surprisingly, these compounds showed better antimycotic activities than the reference drug, fluconazole. In particular, compounds **41** (0.64 μM) and **42** (0.532 μM) demonstrated promising antifungal activity. The tested compounds exhibit higher antifungal activity against *A. flavus* than against *C. albicans*.⁷⁰ A series of benzylbenzofurylcarboxamido benzoxazole derivatives are reported by Yildiz *et al.* and their antimicrobial activity was determined against some Gram-positive and Gram-negative bacteria and fungi. Among the tested derivatives, **43(a-d)** exhibited higher activity against *P. aeruginosa* than ampicillin (MIC > 500 μg mL⁻¹), rifampicin (MIC > 500 μg mL⁻¹) and ofloxacin (MIC = 62.5 μg mL⁻¹) and had the same potency as gentamycin (MIC = 31.25 μg mL⁻¹). Compound **43c** displayed promising activity

with an MIC value of 15.6 μg mL⁻¹ against drug-resistant *P. aeruginosa*, which is more potent than all standard drugs. Compound **43b**, carrying a benzyl group at the second position of the benzoxazole ring, showed a remarkable antifungal activity. In addition, attaching a hydrogen or bromine on position “R” played a role in obtaining good inhibitory potency. However, substituting position R₁ with a bromine atom, while the main structure was 2-phenylbenzoxazole, decreased the inhibitory effect (Fig. 11).⁷¹

Rangaswamy and co-workers reported the synthesis of a new class of functionalized benzofuranyl methoxy phenyl pyrazole scaffolds. The synthesized compounds were evaluated for antibacterial and antifungal activities by the well plate method in Mueller-Hinton agar. The -chloro, -fluoro, -bromo, and -nitro functionalized derivatives demonstrated better activity, while the others showed less activity against all the tested bacterial strains. Compounds **44a** (*p*-fluoro substituted) and **44b** (*p*-chloro substituted) on the 1-substituted phenyl ring showed significant activity against *P. aeruginosa* and *E. coli* at concentrations of 1 and 0.5 μg mL⁻¹, which was almost 15 times better than the standard drug, streptomycin (12 mm and 17 mm at 0.5 μg mL⁻¹). Compounds **44c** (*p*-bromo substituted) and **44d** (*m*-chloro substituted) exhibited similar activity to that of the standard drug against *E. coli*. As for antibacterial activities, the presence of halogen substituents on the phenyl ring produced better antifungal activity compared to other analogues.⁷²




Fig. 10 Structures of phenyl benzofuran derivatives.




Fig. 11 Structures of compounds (39–43).

Furthermore, a series of benzofuran-based pyrazole derivatives as antibacterial/antifungal agents are reported. The introduction of substituted anilines into the pyrazole ring enhanced the antibacterial activity. Compounds **45a** and **45b**, possessing *p*-chloro and *p*-fluoro substituents on the 1-substituted phenyl ring, showed excellent activity against *P. aeruginosa* and *E. coli* at concentrations of 1 and 0.5 $\mu\text{g mL}^{-1}$. The activity is considerably affected by halogen substituents present at the *para* position of the phenyl ring. In the case of compound **45b**, fluoro substituent on the *para*-position of phenyl ring accounted for the enhanced antifungal activity against *C. albicans* as compared to the standard drug, fluconazole.⁷³ Kirilmis and co-workers designed mesitylene-substituted benzofuran derivatives for antimicrobial activity against *S. aureus*, *E. coli* and *C. albicans*. Among the synthesized compounds, (*E*)-1-(1-benzofuran-2-yl)-2-mesitylethanone-*O*-benzoyloxime (**46**) was found to be the most effective derivative against *S. aureus* and *E. coli* at MIC values of 4 and 32 $\mu\text{g mL}^{-1}$, respectively (Fig. 12).⁷⁴

Koca *et al.*, developed a series of benzofuran-ketoxime derivatives as effective antimicrobial agents and among the reported ones, compound **51a** exhibited promising activity (MIC = 0.039 $\mu\text{g mL}^{-1}$) against *S. aureus*. The compounds **47**, **48**, **49b**, **49c**, **50** and **51b** revealed almost the same antimicrobial effect against *C. albicans* (0.625 $\mu\text{g mL}^{-1}$). Compound **49a** displayed a good antimicrobial effect against *C. albicans* (2.5 $\mu\text{g mL}^{-1}$).⁷⁵ The synthesis and antimicrobial efficacies of a series of benzodifuran amide derivatives are reported by Soni *et al.* These compounds exhibited higher MIC values (600 $\mu\text{g mL}^{-1}$) against Gram-negative bacteria *P. aeruginosa* and fungus *C. albicans*. A SAR study revealed that the presence of an electron-withdrawing group at the *para* position of amine is responsible for their moderate activity against Gram-positive bacteria *B. subtilis* (**52a–c**), while the presence of an electron-releasing group at the *para* position of the amine resulted in moderate activity against *S. aureus* (Fig. 13).⁷⁶

Triheterocycles with coumarin, benzofuran and furan rings are reported by Khan and co-workers. The synthesized




Fig. 12 Structures of phenyl benzofuran-pyrazole and mesitylene-benzofuran derivatives.




Fig. 13 Structures of benzofuran-cyclobutyl ketoxime and benzodifuran amide derivatives.

compounds were screened against two bacterial and two fungal species by the standard cup plate method. Introduction of monochloro and dichloro substituents on the benzofuran ring enhanced the antimicrobial potency against *Pseudomonas chinchori*, *A. fumigatus*, and *P. wortmanni*. Among the reported compounds, **53a–e** exhibited considerable inhibition of the microbial growth of all the species at $50 \mu\text{g mL}^{-1}$ concentration. SAR studies showed that the chlorination of the benzofuran ring enhances both the antibacterial and antifungal potencies of the triheterocycles.⁷⁷ Angularly fused polycyclic heterocycles with coumarin, benzofuran and pyridine rings **54a–f** are also reported as antimicrobial agents. All the synthesized compounds exhibited anti-microbial activity against *P. chinchori* at an MIC of $25 \mu\text{g mL}^{-1}$, and for antifungal screening, the growth inhibition was found at $25 \mu\text{g mL}^{-1}$ concentration against *A. fumigatus*, whereas for *P. wortmanni*, these derivatives were found to be active at a concentration of $100 \mu\text{g mL}^{-1}$.⁷⁸

Abdel-Wahab *et al.* reported the synthesis of a series of benzofuranyl nitro arylbutanones and benzofuranyl dihydro aryl thiazolyl pyrazole derivatives and their antimicrobial activity at $100 \mu\text{g}$ concentration. 1-(Thiazol-2-yl) pyrazoline (**55**) revealed excellent antimicrobial activity against Gram-negative bacteria (with an IZ of 25 mm) and good activity against Gram-positive bacteria (with a IZ of 17 mm). It was concluded that benzofuran, pyrazoline, and thiazole moieties are essential for potential antimicrobial activity.⁷⁹ Furthermore, they reported a series of benzofuranyl pyrazole derivatives as antimicrobial agents. Compounds **56–59** presented promising antifungal activities against *C. albicans*, which were more than the reference compound, fluconazole. Moreover, compounds **58** and **59** exhibited noticeable antibacterial activities against *B. subtilis*, which were better than that of the control, amoxicillin. SAR studies revealed that the benzofuran moieties are essential for antimicrobial activity and an increase in the activity is found with an increase in the number of nitrogen atoms. The

phthalimide moieties in compounds are also found to be beneficial for the potential antimicrobial activities.⁸⁰ On the other hand, benzofuran-thiazole and phenyl pyrazole conjugated compounds as antimicrobial agents are reported. Benzofuran derivatives (**60–65**), produced the highest IZ of 30–40 mm against *C. albicans*, therefore it is concluded that benzofuran, pyrazole and thiazole moieties are beneficial for antimicrobial activity (Fig. 14).⁸¹

Ugale and co-workers developed benzofurano-isatin derivatives as antimicrobial agents. Compound **66a** with a nitro group at C-7 of isatin exhibited significant antibacterial activity against *E. coli* and *P. vulgaris* with the same MIC value of $31.25 \mu\text{g mL}^{-1}$. Moreover, the presence of a fluoro group at the C-7 position in the case of compound **66b** resulted in good activities against *B. subtilis*, *E. coli* and *P. vulgaris* with an MIC value of $31.25 \mu\text{g mL}^{-1}$. This derivative was found to be active when compared to the standard drugs, ampicillin and norfloxacin. A SAR study revealed that the introduction of an electron-withdrawing substituent on the isatin nucleus at the C-5 and C-7 positions enhances the antibacterial potential.⁸² Shanker Rao and co-workers reported the synthesis of imidazole/thiazole-benzofuran-conjugated compounds and their antibacterial and antifungal activities. Compounds **67a** and **68a** exhibited an excellent effect on *S. aureus*, *P. aeruginosa* and *Enterococcus faecalis* (*E. faecalis*) bacterial strains. Compounds **67c** and **68a** exhibited effective antimicrobial activity against *S. aureus* and *E. coli*. Antifungal activity was shown against two human pathogen fungal species, *A. niger* and *T. viride*. Compounds **67(a,b)** and **68b** showed significant activities against both the tested organisms.⁸³ In continuation of this study on benzofuran, they also reported the synthesis of a thiazolidinone nucleus bridged with quinoline and benzofuran. Compounds **69a** and **70** showed the highest activities against *Klebsiella pneumoniae*, whereas compounds **69d** and **70** exhibited the highest activities against *E. coli*. Amongst the antifungal




Fig. 14 Structures of compounds (53–65).

activity results, compound **70** demonstrated the highest activity against *A. niger*, and compounds **69a**, **69d** and **70** showed the highest activity against *C. albicans*. Compound **69c** exhibited very good activity against *P. chrysozenous*, while compounds **69b** and **70** displayed the highest activity against *T. vridar*.⁸⁴ Imidazole-substituted benzofuran-conjugated compounds are reported along with their antimicrobial potentials. Compounds **71(b,c)** displayed an effective IZ against *B. subtilis*, while

compounds **71a**, **71c** and **71d** presented a similar level of activity against *F. moniliforme*. Compound **71b** showed comparatively higher activity against *T. viride* and *F. moniliforme*. From the SAR, the activity was increased by the presence of halo (-I, -Br and -Cl) groups as substituents at the R and R₂-positions on the benzene ring, and methyl groups at the R₁ or R₂ positions in combination with -I and -Br at the R position enhanced the activity (Fig. 15).⁸⁵




Fig. 15 Structures of compounds (56–71).

Hadj-Esfandiari and co-workers reported the synthesis of 5-nitroimidazolebenzofuranone and 4-nitroimidazolebenzofuranone derivatives and their antibacterial activity against Gram-positive and Gram-negative bacteria. All 5-nitroimidazole analogues showed remarkable inhibition, evincing their potential antimicrobial activity. Benzofuran with a 4-nitroimidazole core or phenyl group exhibited antibacterial activity with an MIC of 100 μg mL⁻¹. Benzofuranone, **72**, was slightly more effective in inhibiting the growth of *K. pneumoniae* with an MIC of 0.39 μg mL⁻¹, which is 2- to 8-fold higher than the 5-nitrobenzimidazole derivatives against Gram-positive bacteria. The antibacterial activity was enhanced by the negative charge of -NO₂ group on the C-5 position of imidazole; a partial charge on the carbonyl oxygen in benzofuran is necessary for the activity.⁸⁶ Manna and co-workers reported the synthesis of quinoxalino/benzofuran-pyrazole derivatives under microwave conditions; their antibacterial activity was evaluated against seven different multidrug-resistant organisms in various concentrations and results were compared with standard fluoroquinolone drugs. Among the reported compounds, **73(a-e)** showed better activities against *E. coli*, *P. aeruginosa*, *S. typhi* and *S. aureus*. A SAR study revealed that *ortho* substitution in the phenyl ring with -OH or -NO₂ and *para* substitution on the phenyl ring by -OCH₃ at the 5-position of the pyrazole ring evidenced the best antibacterial activity against Gram-negative bacteria.⁸⁷ Aminopyridine-benzofuran derivatives **74(a-e)** were prepared under microwave-assisted synthetic protocols and were tested for their antimicrobial activity against *P. aeruginosa* and *S. aureus*; none of these compounds exhibited good antimicrobial activity.⁸⁸ Basavaraja *et al.* reported a series of oxadiazole and pyrazole derivatives incorporating a benzofuran core as microbial agents. The compounds bearing chloro-substitution, **75a**, and a hydroxyl group, **75b**, exhibited potent antimicrobial activity.⁸⁹ Abdel-Aziz and co-workers synthesized 2-substituted-3-methylbenzofuran derivatives and screened

their antimicrobial activity. The highest antifungal and antibacterial activities were demonstrated by an ethoxymethylene derivative, **76**, and an ethylene derivative, **77**, respectively. The presence of a pyrazole moiety beside the benzofuran ring (in the cases of **78** and **79**) imparts high antifungal and antibacterial activities. The significant antimicrobial activity of **77** and **80** may be due to the presence of benzofuran moieties in addition to the hydrazide function in both the derivatives.⁹⁰ Furthermore, they reported the stereoselective synthesis of benzofuran-based piperidinyl arylamidrazones and tested them for *in vitro* antimicrobial activity. Compound **81** showed a low MIC (25 μg mL⁻¹) against *A. fumigatus* and revealed an MIC of 75 μg mL⁻¹ against *C. albicans*, compared with the standard drug, griseofulvin, which showed MIC of 50 and 75 μg mL⁻¹ against *A. fumigatus* and *C. albicans*, respectively. From an SAR study, it is concluded that both the piperidine moiety and the 4-nitrophenylhydrazine function were essential for the antimicrobial activity (Fig. 16).⁹¹

Rida and co-workers studied a series of benzofuran derivatives containing heterocyclic ring substituents linked to a benzofuran nucleus at the C-2 position by a two- to four-atom spacer as potential antimicrobial agents. Compounds were evaluated for their *in vitro* activity against *S. aureus*, Gram-positive bacteria, *E. coli*, Gram-negative bacteria, and *C. albicans*, a fungus, and ampicillin and clotrimazole were used as reference drugs. Compound **82** exhibited less activity against *S. aureus* with an MIC of 500 μg mL⁻¹. A SAR study revealed that the presence of a spacer between the heterocyclic substituent and the benzofuran nucleus may be essential for the biological activity.⁹² Bis-benzofuran-thiadiazine derivatives were reported as antibacterial and antifungal agents. Compounds containing the phenyl (**83a**), methoxyphenyl (**83b**) and bromophenyl (**83c**) substituents at the C-3 position of a triazolo-thiadiazine ring demonstrated promising activity against bacterial and fungal strains. Compound **83b** is highly active against all the tested




Fig. 16 Structures of compounds (72–81).

organisms employed and the IZ was found to be greater than the standard drug, neomycin.⁹³ 2-Substituted and diacetyl benzofurans are reported by Khan *et al.*, using palladium-catalyzed reactions. The compounds demonstrated mild to significant growth inhibition against Gram-positive and Gram-negative bacteria. An isomeric mixture of diacetylbenzofurans emerged as the most potent microbial agent. In particular, 2,3-

diacetylbenzofuran (**84**) was the most potent compound. From this data, it is concluded that the catalytic sites for benzofurans in the target biomolecule are those with at least one hydrophobic pocket and two H-bond donors—a polar hydroxylated and an imino nitrogen containing amino acid residues. Moreover, substitution at the C_{4–7} positions of the benzofuran ring and the replacement of a 3-acetyl group by other acyl/lower alkyl




Fig. 17 Structures of compounds (82–84).




Fig. 18 Structures of compounds (85–94).

functionalities are to be envisaged for functional characterization of the target biomolecule (Fig. 17).⁹⁴

A series of fluorine-substituted benzofuran chalcones, benzofuran-pyrazoles and benzofuran-isoxazoles were synthesized and screened for their antibacterial and antifungal activity, and the results were compared with standards, ampicillin and griseofulvin. Compound **85a** displayed good activity with an MIC of 62.5 $\mu\text{g mL}^{-1}$ against *S. typhi* and *S. pyogenes*, whereas compounds **85b** and **86(a,b)** showed similar antibacterial activity to the reference drug, ampicillin. For antifungal

activity, compounds **85c**, **86c**, **87a** and **87b** exhibited better activity than the reference drug, griseofulvin, against *C. albicans*.⁹⁵ Furthermore, a series of fluorine-containing benzofuran-pyrimidine conjugates as antimicrobial agents are reported. Compounds **88(a-c)** showed excellent antibacterial activities against *S. pyogenes*, which were similar to the activity of the reference drug, ampicillin. With respect to antifungal activity, compounds **88(b,c)** showed similar activity against *C. albicans*.⁹⁶ Benzofuran-salicylic acid derivatives as antimicrobial agents were described by Hassan and co-workers. Azo derivatives **89(a-**




Fig. 19 Structures of benzofuran-based metal complexes as antimicrobial agents.

c) exhibited good antibacterial activity against both Gram-positive and Gram-negative bacteria and compound **90** demonstrated a promising antifungal activity. A SAR study revealed that the substitution of salicylic acid with an amino group either at position C-5, C-4, or C-3 improved the antimicrobial activity.⁹⁷ Kenchappa *et al.* demonstrated the synthesis and antimicrobial activity of benzofuran barbitone/thiobarbitone derivatives. Compounds **91(a,b)**, having two bromo substituents on C-5 of benzofuran and C-4 of the phenyl ring, respectively, were found to exhibit excellent antibacterial activity against all the tested bacterial strains with MIC values ranging between 29.76 and 31.96 μmol L⁻¹. The same compounds also exhibited equipotent activity against all fungal strains with MIC values in the range of 12.50–66.49 μmol L⁻¹. SAR studies revealed that substitution at the *ortho* position of benzofuran ring and the *para* position of aryl ring was responsible for the increased antimicrobial activity. Compounds containing two bromo substituents have increased antimicrobial activity compared to those bearing a single halogen/other substituent group.⁹⁸ The same group also developed β-amino carbonyl derivatives of benzofuran as antimicrobial agents. From these studies, it is concluded that the electron-withdrawing groups substituted on the aromatic ring, particularly at the *para* position, **92(a–c)**, exhibited potential antimicrobial activity.⁹⁹ Srinivas and co-workers investigated the synthesis of benzofuran-isoxazole and tested its antibacterial and antifungal activity using a serial tube dilution technique; results were compared with ampicillin and fluconazole as a reference standard. Among the tested derivatives, compounds **93a** and **93b** possessed maximum activity, which may be due to

electron-withdrawing substituents such as 2,4-dichlorophenyl and 4-fluorophenyl appended at the C-5 position of isoxazole core. Moreover, the presence of 2-chlorophenyl, 2,4-dichlorophenyl, and 4-nitrophenyl **93a, b** and **d**) at the C-5 position of isoxazole structure resulted in good antifungal activity. This reveals the importance of the electronic effects of the substituents present on the aromatic ring in enhancing the antibacterial/antifungal activity.¹⁰⁰ Kumar *et al.*, invented a series of tricyclic compounds containing benzofuran, benzothiazole and lactum derivatives as antimicrobial agents against *B. subtilis*, *E. coli* and *C. albicans*. Compounds **94(a–c)** exhibited moderate activities with IZ ranging from 11 to 17 mm (Fig. 18).¹⁰¹

5. Benzofuran-based metal complexes as antimicrobial agents

Metal ions play an important role in biochemical processes. Many biochemical reactions depend on the presence of metal ions, which are the part of coordination complexes. Increasing attention has been given in the last decade to the biological applications of benzofuran-based metal complexes including late transition metals such as cobalt(II), nickel(II), copper(II) and zinc(II). Many of these complexes exhibited considerable antibacterial and anticancer properties in *in vitro* and/or *in vivo* assays. The choice of a suitable substitution on the benzofuran-based ligand system is found to be crucial in the design of novel target specific bioactive metal complexes. In this section, the important benzofuran-based ligands and

Table 1 List of novel benzofuran derivatives as antimicrobial agents isolated from natural sources

S.	No. Species	Family	Compound	Reference(s)
1	<i>Cotula coronopifolia</i>	Asteraceae	6-Methoxy-1-benzofuran-4-ol (102)	110
2	<i>Heliotropium filifolium</i>	Boraginaceae	Methyl-3'-hydroxy-2',2',6'-trimethyl-3 <i>H</i> -spiro[1-benzofuran-2,1'-cyclohexane]-5-carboxylate (103), 3'-hydroxy-2',2',6'-trimethyl-3 <i>H</i> -spiro[1-benzofuran-2,1'-cyclohexane]-5-carboxylic acid (104), methyl-3'-acetyloxy-2',2',6'-trimethyl-3 <i>H</i> -spiro[1-benzofuran-2,1'-cyclohexane]-5-carboxylate (105), methyl-3'-isopentanoxyloxy-2',2',6'-trimethyl-3 <i>H</i> -spiro[1-benzofuran-2,1'-cyclohexane]-5-carboxylate (106), methyl-3'-benzoyloxy-2',2',6'-trimethyl-3 <i>H</i> -spiro[1-benzofuran-2,1'-cyclohexane]-5-carboxylate (107)	111
3	<i>Phomopsis</i> sp.	—	3-(Hydroxymethyl)-6,7-dihydrobenzofuran-4(5 <i>H</i>)-one (108)	112
4	<i>Eupatorium aschenbornianum</i>	Asteraceae	5-Acetyl-3β-angeloyloxy-2β-(1-hydroxyisopropyl)-2,3-dihydrobenzofurane (109), 5-acetyl-3β-angeloyloxy-2β-(1-hydroxyisopropyl)-6-methoxy-2,3-dihydrobenzofurane (110)	113
5	<i>Glycyrrhiza</i>	Xibei licorice	4-(6-Hydroxy-4-methoxy-5-(3-methylbut-2-enyl)benzofuran-2-yl)benzene-1,3-diol or licocoumarone (111), 2-(2,4-dimethoxyphenyl)-4,6-dimethoxy-5-(3-methylbut-2-enyl)benzofuran (112)	114
6	<i>Ligularia veitchiana</i>	Compositae	1,3-Dimethoxy-4,6-dimethylnaphthofuran (113)	115
7	<i>Cladonia rangiferina</i>	Cladoniaceae	Didymic acid (114), condidymic acid (115)	116
8	<i>Achyrocline satureioides</i>	Asteraceae	1',1''-[6,7,9-Trihydroxy-8-(2-hydroxy-3-methylbut-3-en-1-yl)-3,3-dimethyl-3 <i>H</i> -benzofuro[2,3- <i>f</i>]chromene-5,10-diyl]bis(2-(<i>S</i>)-methylbutan-1-one) (116), 1',1''-[6,7,9-trihydroxy-8-(2-hydroxy-3-methylbut-dihydroxy)-3,3-dimethyl-3 <i>H</i> -benzofuro[2,3- <i>f</i>]chromene-5,10-diyl]bis(2-(<i>S</i>)-methylbutan-1-one) (117)	117
9	<i>Dalea spinosa</i> (<i>Psorothamnus spinosus</i>)	Fabaceae	Spinosan A (118), spinosan A acetate (119), (+)-medicarpin (120)	118
10	<i>Helianthella quinquenervis</i>	Asteraceae	Euparin (121)	119
11	<i>Stemona aphylla</i>	Stemonaceae	Stemofuran E (122), stemofuran J (123), stemofuran M (124), stemofuran P (125), stemofuran R (126)	120
12	<i>Gnetum gnemon</i> L.	Gnetacea	Stilbenoid (127), gnetin C (128)	121
13	<i>Allium cepa</i>	Alliaceae	2-(3,4-Dihydroxyphenyl)-4,6-dihydroxy-2-methoxybenzofuran-3-one (129)	122
14	<i>Caesalpinia pulcherrima</i>	Leguminosae	Isovouacapenol D or [(4α,5β,11bβ)-1,2,3,4,4a,5,6,11b-octahydro-4,4,7,11b-tetramethylphenanthro[3,2- <i>b</i>]furan-4a,5-diol-5-benzoate] (130)	123
15	<i>Murraya koenigii</i>	Rutaceae	3ε-(1ε-Hydroxyethyl)-7-hydroxy-1-isobenzofuranone (131)	124
16	<i>Calea platylepis</i>	Asteraceae/ Heliantheae	Euparin (132), caleprunin A (133), caleprunin B (134), euparone (135)	125

7. Conclusions and future aspects

Incidences of bacterial and fungal infections have increased significantly in the past 25 years. The evolution of resistance in bacterial strains against currently available antibacterial agents has been an increasing concern in recent years. To overcome the threat of widespread multidrug resistance in Gram positive and Gram negative bacterial strains as well as fungi, there is ongoing demand for new antimicrobial agents. The discovery of novel drugs in many fields, *i.e.* antibacterial, has been stalled for many years. There is an urgent need for new pharmaceuticals that have a broader spectrum of activity or act through novel mechanisms of action, *i.e.* to overcome the increasing incidence of microbial resistance observed for currently used drugs. Numerous outstanding achievements revealed that benzofuran-based compounds have extensive potential as antimicrobial agents. To further optimize the complete potential of benzofuran compounds, SAR-based studies are likely to continue to play an important role. It is very likely that optimized benzofuran compounds with excellent potency and few side effects will continue to be created. Some of these benzofuran compounds will undoubtedly be used as antimicrobial therapeutic agents in the near future. The present review,

covering literature from the last fifteen years, is expected to provide a bird's eye view of benzofuran-derived compounds for drug designers and medicinal chemists as well as comprehensive and target-oriented information for the development of clinically viable molecules. Furthermore, future research in this field will bring innovative pharmaceutical developments with a considerable spectrum of use.

Abbreviations

<i>A. fumigatus</i> (AF)	<i>Aspergillus fumigatus</i>
<i>A. niger</i> (AN)	<i>Aspergillus niger</i>
APB	Aminopropyl benzofuran
APDB	Aminopropyl-2,3-dihydrobenzofuran
<i>B. megaterium</i> (BM)	<i>Bacillus megaterium</i>
BPAP	Benzofuran-2-yl-2-propylaminopentane
<i>B. subtilis</i> (BS)	<i>Bacillus subtilis</i>
<i>C. albicans</i> (CA)	<i>Candida albicans</i>
<i>C. glabrata</i> (CG)	<i>Candida glabrata</i>
DNA	Deoxyribonucleic acid
<i>E. coli</i> (EC)	<i>Escherichia coli</i>
<i>E. feltis</i> (EF)	<i>Escherichia feltis</i>

<i>F. moniliforme</i> (FM)	<i>Fusarium moniliforme</i>
<i>G. candidum</i> (GC)	<i>Geotrichum candidum</i>
HIV	Human immunodeficiency virus
IZ	Inhibition zone
<i>K. pneumoniae</i> (KP)	<i>Klebsiella pneumoniae</i>
MIC	Minimum inhibitory concentration
µg	Micro gram
mL	Milli litre
ML	Micrococcus luteus
mm	Milli metre
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
<i>P. aeruginosa</i> (PA)	<i>Pseudomonas aeruginosa</i>
<i>P. chinchori</i> (PC)	<i>Pseudomonas chinchori</i>
<i>P. vulgaris</i> (PV)	<i>Proteus vulgaris</i>
<i>P. wortmanni</i> (PW)	<i>Pseudomonas wortmanni</i>
<i>S. aureus</i> (SA)	<i>Staphylococcus aureus</i>
SAR	Structure activity relationship
<i>S. cerevisiae</i> (SC)	<i>Saccharomyces cerevisiae</i>
<i>S. pyogenes</i> (SP)	<i>Streptococcus pyogenes</i>
<i>S. racemosum</i> (SR)	<i>Syncephalastrum racemosum</i>
<i>S. typhi</i> (ST)	<i>Salmonella typhimurium</i>
<i>S. mentagrophytes</i> (TM)	Trichophyton mentagrophytes
<i>T. viride</i> (TV)	Trichoderma viride

Acknowledgements

The author RSK thanks Jain University, Bangalore for financial support and author AH is thankful to Erasmus NAMASTE consortium (unique grant number: NAMASTE_20140147) for the award of his doctoral exchange fellowship, while author KC is thankful to Fundação para a Ciência e a Tecnologia (FCT) for funding his postdoctoral research.

References

- Y. He, B. Wu, J. Yang, D. Robinson, L. Risen, R. Ranken, L. Blyn, S. Sheng and E. E. Swayze, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 3253–3256.
- B. P. Mathew and M. Nath, *ChemMedChem*, 2009, **4**, 310–323.
- I. Berber, C. Cokmus and E. Atalan, *Microbiol.*, 2003, **72**, 42–47.
- W. S. Sung, H. J. Jung, K. Park, H. S. Kim, L. S. Lee and D. G. Lee, *Life Sci.*, 2007, **80**, 586–591.
- W. H. Perkin, *J. Chem. Soc.*, 1870, **23**, 368–371.
- B. A. Keay, J. M. Hopkins and P. W. Dibble, in *Comprehensive heterocyclic chemistry III*, ed. A. R. Katritzky, C. A. Ramsden, E. F. V. Scriven and R. J. K. Taylor, Elsevier, Oxford, 2008.
- (a) S. Shimazu, K. Takahata, H. Katsuki, H. Tsunekawa, A. Tanigawa, F. Yoneda, J. Knoll and A. Akaike, *Eur. J. Pharmacol.*, 2001, **421**, 181–189; (b) S. Shimazu, H. Tsunekawa, F. Yoneda, H. Katsuki, A. Akaike and A. Janowsky, *Eur. J. Pharmacol.*, 2003, **482**, 9–16; (c) J. Knoll, F. Yoneda, B. Knoll, H. Ohde and I. Miklya, *Br. J. Pharmacol.*, 1999, **128**, 1723–1732.
- C. Ryu, A. Song, J. Y. Lee, J. Hong, J. H. Yoon and A. Kim, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 6777–6780.
- (a) B. F. Abdel-Wahab, H. A. Abdel-Aziz and E. M. Ahmed, *Eur. J. Med. Chem.*, 2009, **44**, 2632–2635; (b) F. Pan and T. C. Wang, *J. Chin. Chem. Soc.*, 1961, **8**, 220–225; F. Pan and T. C. Wang, *J. Chin. Chem. Soc.*, 1961, **8**, 374–379.
- (a) K. Manna and Y. K. Agrawal, *Eur. J. Med. Chem.*, 2010, **45**, 3831–3839; (b) M. Brandvang, V. Bakken and L. L. Gundersen, *Bioorg. Med. Chem. Lett.*, 2009, **17**, 6512–6516; S. M. Bakunova, S. A. Bakunov, T. Wenzler, T. Barszcz, K. A. Werbovets, J. E. Reto Brun Hall and R. R. Tidwell, *J. Med. Chem.*, 2007, **50**, 5807–5823.
- F. A. Ragab, N. M. Eid, G. S. Hassan and Y. M. Nissan, *Chem. Pharm. Bull.*, 2012, **60**, 110–120.
- K. M. Dawood, H. Abdel-Gawad, E. A. Rageb, M. Ellithey and H. A. Mohamed, *Bioorg. Med. Chem.*, 2006, **14**, 3672–3680.
- M. O. Abdelhafez, K. M. Amin, H. I. Ali, M. M. Abdallad and E. Y. Ahmed, *RSC Adv.*, 2014, **4**, 11569–11579.
- S. M. Rida, S. A. El-Hawash, H. T. Fahmy, A. A. Hazza and M. M. El-Meligy, *Arch. Pharmacol. Res.*, 2006, **29**, 16–25.
- S. Rádl, P. Hezký, P. Konvička and I. Krejčí, *Chem. Commun.*, 2000, **65**, 1093–1108.
- S. P. Gibson and C. Laurate, Benzofuran antiparasitic agents, WO/2008/102232, 2008.
- K. V. Sashidhara, R. K. Modukuri, R. Sonkar, K. B. Rao and G. Bhatia, *Eur. J. Med. Chem.*, 2013, **68**, 38–46.
- S. S. Rindhe, M. A. Rode and B. K. Karale, *Indian J. Pharm. Sci.*, 2010, **72**, 231–235.
- K. A. Reddy, B. B. Lohray, V. Bhushan, A. C. Bajji, K. V. Reddy, P. R. Reddy, T. H. Krishna, I. N. Rao, H. K. Jajoo, N. V. Rao, R. T. Chakrabarti, D. Kumar and R. Rajagopalan, *J. Med. Chem.*, 1999, **42**, 1927–1940.
- B. C. Ross, D. Middlemiss, D. I. C. Scopes, T. I. M. Jack, K. S. Cardwell, M. D. Dowle, J. G. Montana, M. Pass and D. B. Judd, EP, 0514197 A1, 1992.
- S. Ravikumar, G. Ramanathan and M. Gnanadesigan, *Asian Pac. J. Trop. Med.*, 2012, **5**, 358–361.
- M. Ono, M. P. Kung, C. Hou and H. F. Kung, *Nucl. Med. Biol.*, 2002, **29**, 633–642.
- M. B. Isman, P. Proksch and L. Witte, *Arch. Insect Biochem. Physiol.*, 1987, **6**, 109–120.
- M. B. Isman, in *Insecticides of plant origin*, J. T. Arnason, B. J. R. Philogène and P. Morand, ACS Symposium Series 387, Washington, DC, 1989, pp. 44–58.
- K. Suzuki, T. Okawara, T. Higashijima, K. Yokomizo, T. Mizushima and M. Otsuka, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 2065–2068.
- K. S. C. Marriott, A. Z. Morrison, M. Moore, O. Olubajo and L. E. Stewart, *Bioorg. Med. Chem. Lett.*, 2012, **20**, 6856–6861.
- Y. Xiang, B. Hirth, G. Asmussen, H.-P. Biemann, K. A. Bishop, A. Good, M. Fitzgerald, T. Gladysheva, A. Jain, K. Jancsics, J. Liu, M. Metz, A. Papoulis, R. Skerlj, J. D. Stepp and R. R. Wei, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 3050–3056.

- 28 K. Asoh, M. Kohchi, I. Hyoudoh, T. Ohtsuka, M. Masubuchi, K. Kawasaki, H. Ebiike, Y. Shiratori, T. A. Fukami, O. Kondoh, T. Tsukaguchi, N. Ishii, Y. Aoki, N. Shimma and M. Sakaitani, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 1753–1757.
- 29 M. Sun, C. Zhao, G. A. Gfesser, C. Thiffault, T. R. Miller, K. Marsh, J. Wetter, M. Curtis, R. Faghieh, T. A. Esbenshade, A. A. Hancock and M. Cowart, *J. Med. Chem.*, 2005, **48**, 6482–6490.
- 30 S. L. Graham, J. M. Hoffman, P. Gautheron, S. R. Michelson, T. H. Scholz, H. Schwam, K. L. Shepard, A. M. Smith and R. L. Smith, *J. Med. Chem.*, 1990, **33**, 749–754.
- 31 B. Pourabas and A. Banihashemi, *Polym. Int.*, 2002, **51**, 1086–1099.
- 32 J. Xu, G. Nie, S. Zhang, X. Han, S. Pu, L. Shen and Q. Xiao, *Eur. Polym. J.*, 2005, **41**, 1654–1661.
- 33 C. H. Chen, N. Y. Fairport, L. J. Fox and M. Balmnore, Novel benzofuran dyes, *US Pat.*, 4900831 A, 1990.
- 34 C. H. Chen and J. L. Fox, Novel benzofuran dyes, *US Pat.*, 4948893 A, 1990.
- 35 R. Sato, K. Kato, T. Sasaki and H. Sugit, Silver halide photosensitive materials for color photography, EP, 0148536 A2, 1985.
- 36 H. Odenwalder, H. Langen, J. Hagemann and K. Henseler, Color photographic silver halide, material, *US Pat.*, 5981160 A, 1999.
- 37 P. S. Song and K. J. Tapley Jr, *Photochem. Photobiol.*, 1979, **29**, 1177–1197.
- 38 F. P. Gasparro, R. Dallamico, D. Goldminz, E. Simmons and D. Weingold, *Yale J. Biol. Med.*, 1989, **62**, 579–593.
- 39 S. Caffieri, *Photochem. Photobiol. Sci.*, 2002, **1**, 149–157.
- 40 L. Santana, E. Uriarte, F. Roleira, N. Milhazes and F. Borges, *Curr. Med. Chem.*, 2004, **11**, 3239–3261.
- 41 E. M. Bickoff, A. N. Booth, R. L. Lyman, A. L. Livingston, C. R. Thompson and F. Deeds, *Science*, 1957, **126**, 969–970.
- 42 J. W. Mason, *N. Engl. J. Med.*, 1987, **316**, 455–566.
- 43 F. Bogazzi, L. Tomisti, L. Bartalena, F. Aghini-Lombardi and E. Martino, *J. Endocrinol. Invest.*, 2012, **35**, 340–348.
- 44 C. Mitsui, J. Soeda, K. Miwa, H. Tsuji, J. Takeya and E. Nakamura, *J. Am. Chem. Soc.*, 2012, **134**, 5448–5451.
- 45 F. Yoneda, J. Knoll, H. Ode, M. Sakae, M. Katurada, T. Moto, T. Ando, S. Shimazu, K. Takahata and M. Fujimoto, Ethylamine derivatives, *US Pat.*, 6214859, 2001.
- 46 A. P. Monte, D. Marona-Lewicka, N. V. Cozzi and D. E. Nichols, *J. Med. Chem.*, 1993, **36**, 3700–3706.
- 47 P. Dawson, J. Opacka-Juffry, J. D. Moffatt, Y. Daniju, N. Dutta, J. Ramsey and C. Davidson, *Prog. Neuro-Psychopharmacol. Biol. Psychiatry*, 2014, **48**, 57–63.
- 48 L. Iversen, S. Gibbons, R. Treble, V. Setola, X. P. Huang and B. L. Roth, *Eur. J. Pharmacol.*, 2012, **700**, 147–151.
- 49 K. Briner, J. P. Burkhardt, T. P. Burkholder, M. J. Fisher, W. H. Gritton, D. T. Kohlman, S. X. Liang, S. C. Miller, J. T. Mullaney, Y. C. Xu and Y. Xu, *US Pat.*, 7045545, 2006.
- 50 (a) R. Naik, D. S. Harmalkar, X. Xu, K. Jang and K. Lee, *Eur. J. Med. Chem.*, 2015, **90**, 379–393; (b) A. Radadiya and A. Shah, *Eur. J. Med. Chem.*, 2015, **97**, 356–376; (c) R. J. Nevagi, S. N. Dighe and S. N. Dighe, *Eur. J. Med. Chem.*, 2015, **5**, 561–581; (d) K. M. Dawood, *Expert Opin. Ther. Pat.*, 2013, **23**, 1133–1156; (e) M. G. Kadieva and É. T. Oganessian, *Chem. Heterocycl. Compd.*, 1997, **33**, 1245–1258; (f) H. Khanam and Shamsuzzaman, *Eur. J. Med. Chem.*, 2015, **5**, 483–504.
- 51 (a) N. G. Karaburun, K. Benkli, Y. Tunalı, Ü. Uçucu and Ş. Demirayak, *Eur. J. Med. Chem.*, 2006, **41**, 651–656; (b) D. Bogdal and M. Warzala, *Tetrahedron*, 2000, **56**, 8769–8773; (c) A. R. Katrizky, Y. Ji, Y. Fang and I. Prakash, *J. Org. Chem.*, 2001, **66**, 5613–5615; (d) K. Ando, Y. Kawamura, Y. Akai, J. Kunitomo, T. Yokomizo, M. Yamashita, S. Ohta, T. Ohishi and Y. Ohishi, *Org. Biomol. Chem.*, 2008, **6**, 296–307.
- 52 (a) W. Boehme, *Org. Synth.*, 1953, **33**, 43–46; (b) R. Adams and L. Whitaker, Quinone Imides. XXXIX. Adducts of quinone monoimides and conversion of active methylene adducts to benzofurans, *J. Am. Chem. Soc.*, 1956, **78**, 658–663.
- 53 (a) A. Arcadi, S. Cacchi, M. D. Rosario, G. Fabrizi and F. Marinelli, *J. Org. Chem.*, 1996, **61**, 9280–9288; (b) C. Amatore, E. Blart, J. P. Genet, A. Jutand, S. Lemaire-Audoire and M. Savignac, *J. Org. Chem.*, 1995, **60**, 6829–6839; (c) A. Sogawa, M. Tsukayama, H. Nozaki and M. Nakayama, *Heterocycles*, 1996, **43**, 101–111; (d) S. Cacchi, G. Fabrizi and L. Moro, *Tetrahedron Lett.*, 1998, **39**, 5101–5104; (e) A. Furstner and P. W. Davies, *J. Am. Chem. Soc.*, 2005, **127**, 15024–15025; (f) J. Oppenheimer, W. Johnson, M. Tracey, R. Hsung, P. Y. Yao, R. Liu and K. Zhao, *Org. Lett.*, 2007, **9**, 2361–2364; (g) V. Patel, G. Pattenden and J. Russell, *Tetrahedron Lett.*, 1986, **27**, 2303–2306.
- 54 A. Weissberger and E. C. Taylor, *Chemistry of heterocyclic compounds*, John Wiley & Sons, New York, vol. 29, 1974.
- 55 P. Froberg, C. Kupfer, P. Stenger, U. Baumeister and P. Nuhn, *Arch. Pharm.*, 1995, **328**, 505–516.
- 56 J. Debord, P. N. Diaye, J. C. Bollinger, K. Fikri, B. Penicaut, J. M. Robert, P. S. Robert and G. le-Baut, *J. Enzyme Inhib. Med. Chem.*, 1997, **12**, 13–26.
- 57 E. S. H. El Ashry, N. A. Rashed and H. S. Shobier, *Pharmazie*, 2000, **55**, 403–415.
- 58 J. M. Robert, O. Rideau, S. R. Piessard, M. Duflos, G. LeBaut, N. Grimaud, M. Juge and J. Y. Petit, *Arzneim.-Forsch./Drug Res.*, 1997, **47**, 635–642.
- 59 H. A. Mohamed, E. Abdel-Latif, B. F. Abdel-Wahab and G. E. A. Awad, *Int. J. Med. Chem.*, 2013, DOI: 10.1155/2013/986536.
- 60 E. P. Davies, J. D. Pittam, K. B. Mallion and N. P. Taylor, Process for preparing an antifungal azole with hydrazino and amidrazone intermediates, *US Pat.*, 5861516, 1999, p. 19.
- 61 V. N. Telvekar, A. Belubbi, V. K. Bairwa and K. Satardekar, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 2343–2346.
- 62 M. G. Mamolo, V. Falagiani, L. Vio and E. Banfi, *Farmaco*, 1999, **54**, 761–767.
- 63 D. Ranft, G. Lehwark-Yvetot, K. J. Schaper and A. Buge, *Arch. Pharm.*, 1997, **330**, 169–172.

- 64 D. Ranft, T. Seyfarth, K. Schaper, G. Lehwark-Yvetot, C. Bruhn and A. Buge, *Arch. Pharm.*, 1999, **332**, 427–430.
- 65 H. A. Abdel-Aziz and A. A. I. Mekawey, *Eur. J. Med. Chem.*, 2009, **44**, 4985–4997.
- 66 J. Liu, F. Jiang, X. Jiang, W. Zhang, J. Liu, W. Liu and L. Fu, *Eur. J. Med. Chem.*, 2012, **54**, 879–886.
- 67 X. Jiang, W. Liu, W. Zhang, F. Jiang, Z. Gao, H. Zhuang and L. Fu, *Eur. J. Med. Chem.*, 2011, **46**, 3526–3530.
- 68 A. Chandrashekar, E. Bheemappa, Y. D. Bodke, V. K. Bhovi, R. Ningegowda, M. C. Shivakumar, S. K. Peethambar and S. Telkar, *Med. Chem. Res.*, 2013, **22**, 78–87.
- 69 V. K. Reddy, J. V. Rao, L. B. Reddy, B. Ram and B. Balram, *Pharma Chem.*, 2013, **5**, 237–242.
- 70 S. S. El-Nakkady, H. F. Roaiah, W. S. El-Serwy, A. M. Soliman, S. I. Abd-El-Moez and A. A. Abdel-Rahman, *Acta Pol. Pharm.*, 2012, **69**, 645–655.
- 71 S. Alper-Hayta, M. Arisoy, Ö. Temiz-Arpaci, I. Yildiz, E. Aki, S. Özkan and F. Kaynak, *Eur. J. Med. Chem.*, 2008, **43**, 2568–2578.
- 72 J. Rangaswamy, H. Vijay Kumar, S. T. Harini and N. Naik, *Arabian J. Chem.*, 2013, DOI: 10.1016/j.arabjc.2013.10.012.
- 73 J. Rangaswamy, H. Vijay Kumar, S. T. Harini and N. Naik, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 4773–4777.
- 74 C. Kirilmis, M. Ahmedzade, S. Servi, M. Koca, A. Kizirgil and C. Kazaz, *Eur. J. Med. Chem.*, 2008, **43**, 300–308.
- 75 M. Koca, S. Servi, C. Kirilmis, M. Ahmedzade, C. Kazaz, B. Özbek and G. Ötük, *Eur. J. Med. Chem.*, 2005, **40**, 1351–1358.
- 76 J. N. Soni and S. S. Soman, *Eur. J. Med. Chem.*, 2014, **75**, 77–81.
- 77 I. A. Khan, M. V. Kulkarni and C. M. Sun, *Eur. J. Med. Chem.*, 2005, **40**, 1168–1172.
- 78 I. A. Khan, M. V. Kulkarni, M. Gopal, M. S. Shahabuddin and C. M. Sun, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 3584–3587.
- 79 B. F. Abdel-Wahab, H. A. Abdel-Aziz and E. M. Ahmed, *Eur. J. Med. Chem.*, 2009, **44**, 2632–2635.
- 80 B. F. Abdel-Waha, H. A. Abdel-Aziz and E. M. Ahmed, *Arch. Pharm. Chem. Life Sci.*, 2008, **341**, 734–739.
- 81 B. F. Abdel-Wahab, H. A. Abdel-Aziz and E. M. Ahmed, *Monatsh. Chem.*, 2009, **140**, 601–605.
- 82 V. Ugale, H. Patel, B. Patel and S. Bari, *Arabian J. Chem.*, 2012, DOI: 10.1016/j.arabjc.2012.09.011.
- 83 S. Shankerrao, Y. D. Bodke and S. Santoshkumar, *Arabian J. Chem.*, 2012, DOI: 10.1016/j.arabjc.2012.10.018.
- 84 V. K. Bhovia, Y. D. Bodke, S. Biradar, B. E. Kumaraswamy and S. Umesh, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2010, **185**, 110–116.
- 85 B. S. Dawane, S. G. Konda, N. T. Khandare, S. S. Chobe, B. M. Shaikh, R. G. Bodade and V. D. Joshi, *Org. Commun.*, 2010, **3**, 22–29.
- 86 N. Hadj-Esfandiari, L. Navidpour, H. Shadnia, M. Amini, N. Samadi, M. A. Faramarzi and A. Shafiee, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 6354–6363.
- 87 K. Manna and Y. K. Agrawal, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 2688–2692.
- 88 D. B. Arun Kumar, G. K. Prakash, M. N. Kumaraswamy, B. P. Nandeshwarappa, B. S. Shrigara and K. M. Mahadevan, *Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem.*, 2006, **45**, 1699–1703.
- 89 H. Hanumanagoud and K. M. Basavaraj, *Pharma Chem.*, 2013, **5**, 87–98.
- 90 H. A. Abdel-Aziz, A. A. I. Mekawey and K. M. Dawood, *Eur. J. Med. Chem.*, 2009, **44**, 3637–3644.
- 91 H. A. Abdel-Aziz and A. A. I. Mekawey, *Eur. J. Med. Chem.*, 2009, **44**, 4985–4997.
- 92 S. M. Rida, S. A. M. El-Hawash, H. T. Y. Fahmy, A. A. Hazza and M. M. M. El-Meligy, *Arch. Pharmacol. Res.*, 2006, **29**, 826–833.
- 93 C. S. Reddy, D. Chandrasekhar Rao, V. Yakub and A. Nagaraj, *Acta Chim. Slov.*, 2011, **58**, 582–589.
- 94 M. W. Khan, M. J. Alam, M. A. Rashid and R. Chowdhury, *Bioorg. Med. Chem.*, 2005, **13**, 4796–4805.
- 95 T. S. Chundawat, N. Sharma and S. Bhagat, *Med. Chem. Res.*, 2014, **23**, 1350–1359.
- 96 T. S. Chundawat, N. Sharma and S. Bhagat, *Med. Chem.*, 2014, **10**, 409–417.
- 97 G. S. Hassan and G. A. Soliman, *Eur. J. Med. Chem.*, 2010, **45**, 4104–4112.
- 98 R. Kenchappa, Y. D. Bodke, B. Asha, S. Telkar and M. A. Sindhe, *Med. Chem. Res.*, 2014, **23**, 3065–3081.
- 99 R. Kenchappa, Y. D. Bodke, S. K. Peethambar, S. Telkar and V. K. Bhovi, *Med. Chem. Res.*, 2013, **22**, 4787–4797.
- 100 M. Srinivas, D. Swapna, K. Haritha and K. Rao, *PHARMANEST*, 2013, **4**, 1219–1228.
- 101 D. R. Harish Kumar and M. D. Karvelar, *Eur. J. Chem.*, 2010, **7**, 636–640.
- 102 M. B. Halli and Z. S. Qureshi, *Indian J. Chem., Sect. A: Inorg., Bio-inorg., Phys., Theor. Anal. Chem.*, 2004, **43**, 2347–2351.
- 103 M. B. Halli, V. B. Patil, M. Kinni and R. B. Sumathi, *J. Coord. Chem.*, 2011, **64**, 651–662.
- 104 M. B. Halli and R. S. Malipatil, *Pharma Chem.*, 2011, **3**, 146–157.
- 105 M. B. Halli, V. B. Patil and S. R. Bevinamaradha, *Turk. J. Chem.*, 2011, **35**, 393–404.
- 106 M. B. Halli, R. S. Malipatil and R. B. Sumathi, *Int. J. Pharma Bio Sci.*, 2012, **3**, 547–557.
- 107 S. Goel, S. Chandra and S. D. Dwivedi, *J. Saudi Chem. Soc.*, 2013, DOI: 10.1016/j.jscs.2013.07.005.
- 108 (a) M. Takanashi, Y. Takizawa and T. Mitsuhashi, *Chem. Lett.*, 1974, **8**, 869–871; (b) Y. Luo, Z. He and H. Li, *Fitoterapia*, 2007, **78**, 211–214.
- 109 D. H. Choi, J. W. Hwang, H. S. Lee, D. M. Yang and J. G. Jun, *Bull. Korean Chem. Soc.*, 2008, **29**, 1594–1596.
- 110 K. Liouane, K. B. H. Salah, H. B. Abdel-kader, M. A. Mahjoub, M. Aouni, K. Said and Z. Mighri, *Afr. J. Microbiol. Res.*, 2012, **6**, 4662–4666.
- 111 A. Urzúa, J. Echeverría, M. C. Rezende and M. Wilkens, *Molecules*, 2008, **13**, 2385–2393.
- 112 X. Du, C. Lu, Y. Li, Z. Zheng, W. Su and Y. Shen, *J. Antibiot.*, 2008, **61**, 250–253.
- 113 M. Y. Rios, A. B. Aguilar-guadarrama and V. Navarro, *Planta Med.*, 2003, **69**, 967–970.

- 114 S. Demizu, K. Kajiyama, K. Takahashi, Y. Hiraga, S. Yamamoto, Y. Tamura, K. Okada and T. Kinoshita, *Chem. Pharm. Bull.*, 1988, **36**, 3474–3479.
- 115 Q. Liu, L. Shen, T.-T. Wang, J. Chen, W. Y. Qi and K. Gao, *Food Chem.*, 2010, **122**, 55–59.
- 116 K. Yoshikawa, N. Kokudo, M. Tanaka, T. Nakano, H. Shibata, N. Aragaki, T. Higuchi and T. Hashimoto, *Chem. Pharm. Bull.*, 2008, **56**, 89–92.
- 117 C. Casero, F. Machín, S. Méndez-Álvarez, M. Demo, A. G. Ravelo, N. Pérez-Hernández, P. Joseph-Nathan and A. Estévez-Braun, *J. Nat. Prod.*, 2015, **78**, 93–102.
- 118 G. Belofsky, R. Carreno, K. Lewis, A. Ball, G. Casadei and G. P. Tegos, *J. Nat. Prod.*, 2006, **69**, 261–264.
- 119 P. Castaneda, L. Gomez and R. Mata, *J. Nat. Prod.*, 1996, **59**, 323–326.
- 120 T. Sastraruji, S. Chaiyong, A. Jatisatienr, S. G. Pyne, A. T. Ung and W. Lie, *J. Nat. Prod.*, 2011, **74**, 60–64.
- 121 E. Kato, Y. Tokunaga and F. Sakan, *J. Agric. Food Chem.*, 2009, **57**, 2544–2549.
- 122 F. A. Ramos, Y. Takaishi, M. Shirotori, Y. Kawaguchi, K. Tsuchiya, H. Shibata, T. Higuti, T. Tadokoro and M. Takeuchi, *J. Agric. Food Chem.*, 2006, **54**, 3551–3557.
- 123 C. Y. Ragasa, J. G. Hofileña and J. A. Rideout, *J. Nat. Prod.*, 2002, **65**, 1107–1110.
- 124 M. M. Rahman and A. I. Gray, *Phytochemistry*, 2005, **66**, 1601–1606.
- 125 A. M. Do Nascimento, M. J. Salvador, R. C. Candidoc, I. Y. Ito and D. C. R. de Oliveira, *Fitoterapia*, 2004, **75**, 514–519.